Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (522)	7/27/2019 6:35:44 PM
From: BulbaMan	Read Replies (1) of 684

For sure, the CEO’s reputation for deal-making and self-dealing would be a factor. And I assume you agree that not all biotechs with failed drugs also had lousy management. In any case, what I was wondering was whether age was a factor as well. Apparently, you think not. Oh well, another brilliant idea that may not be so brilliant after all. ;~) (The age idea was partly inspired by the IMDZ buyout by Merck at a huge premium. Carlos Paya, IMDZ CEO, was 60 when the buyout was announced and the median age of the IMDZ BOD was 67.) Peace & good health, Bulba

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next